Impact of Atrial Fibrillation on Thrombotic Complications in Myeloproliferative Neoplasms Real-World Analysis - PubMed
3 hours ago
- #Myeloproliferative Neoplasms
- #Atrial Fibrillation
- #Thrombotic Complications
- Philadelphia chromosome-negative myeloproliferative neoplasms (MPN) increase thrombotic risk due to a pro-thrombotic, inflammatory state.
- Atrial fibrillation (AF) in MPN patients leads to higher thrombotic events, mainly arterial (67% vs. 43%, p < 0.0001).
- Despite high thrombosis risk, 36.7% of MPN-AF patients did not receive antiplatelet therapy; cytoreductive therapy did not sufficiently reduce thrombosis.
- AF in MPN is associated with significantly shorter overall survival (181 vs. 265 months, HR: 1.86, p < 0.0001), especially in essential thrombocythemia and MF subtypes.
- Conventional AF management (focusing on anticoagulation) may be inadequate for MPN-AF's arterial phenotype, indicating a need for disease-adapted antithrombotic strategies.
- Prospective studies are required to explore inflammatory and vascular mechanisms contributing to thrombotic risk in MPN-AF.